Request a Consultation
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). Please see the Terms of Use. The method of off-label treatment utilized is a patented invention of the INR. Copyright 2017 INR PLLC, all rights reserved.

Treatment was for chronic pain due to a herniated disc, December 2016.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. Treatment for this indication is off-label. Please see the Terms of Use. Copyright 2017 INR PLLC, all rights reserved. The method of treatment utilized is a patented invention of the INR. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.

About the Institute

In 2003 the INR published the first of its many peer-reviewed scientific publications documenting the INR's medical breakthroughs in the field of neuroinflammation. Since that time scientists around the world have developed supporting evidence that suggests, in accordance with the findings of INR physicians, that dormant circuits in the brain and other parts of the central nervous system, following stroke and other forms of injury, are capable of being re-activated, resulting in rapid neurological improvement. The INR's breakthrough treatment is not experimental: it has been used for thousands of patients from every populated continent in the world.

Hundreds of scientific articles from academic scientists have cited INR publications. In addition to patient care, the INR trains physicians in the proper implementation of its patented, off-label treatment methods. The INR Physician Training Program has been attended by physicians from six continents.

The INR's issued and pending U.S. and foreign patents, include, but are not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8,900,583; Australian patents 758523 and 2011323616 B2, Canadian patent 2,811,948, European patent ES2620749 (T3), etc., all assigned to TACT IP LLC.